According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Individual Participant Data Meta-Analysis of Randomized Controlled Trials
The claim can be definitively tested by pooling raw individual-level data from all major statin RCTs (e.g., JUPITER, HPS, ASCOT, TNT, PROSPER) that include cancer incidence and cancer mortality as pre-specified endpoints. The analysis would stratify participants by baseline LDL (<2.0 mmol/L vs. ≥2.0 mmol/L) and baseline vascular risk (e.g., low, moderate, high, very high using Framingham or SCORE2). The primary outcome would be cancer incidence and cancer-specific death over ≥5 years of follow-up, with adjustment for age, sex, smoking, BMI, and prior cancer history. Prospective, Double-Blind, Placebo-Controlled Randomized Trial in Low-LDL Population
A dedicated RCT enrolling only individuals with baseline LDL <2.0 mmol/L and no prior cancer, randomized to statin vs. placebo, with cancer incidence and cancer death as primary endpoints. This would isolate the effect of statins in the lowest-risk subgroup explicitly mentioned in the claim. Prospective Population-Based Cohort with Long-Term Cancer Surveillance
A large, population-based cohort study tracking statin users and non-users with baseline LDL <2.0 mmol/L over 15+ years, using national cancer registries and death records to minimize ascertainment bias. Nested Case-Control Study within Statin RCTs
To test whether statin exposure is associated with cancer risk specifically in the low-LDL subgroup, using a case-control design nested within existing RCTs to reduce selection bias. Systematic Review with Network Meta-Analysis of Statin Types and Doses
To determine if different statins or doses have differential effects on cancer risk in low-LDL populations, addressing potential heterogeneity in the claim.